OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
12 Nov 2025 | Category: Technology
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89Zr-girentuximab) in metastatic triple negative breast...
🔗 Read More at Original Source
Source:
Pr Newswire Apac
| 12 Nov 2025
Related Articles
Samsung Leaks Confirm Galaxy S26 Cancellation And New Design Boost
Samsung will re-use its Galaxy S25 Edge design technology in the Galaxy S26 series, which means slimmer phones and a new galaxy …
Source:
Forbes
| 12 Nov 2025
Final Audio's new earbuds will inspect your ears to tune your tone to perfection
With its TONALITE system, Final Audio is becoming a timbre merchants
Source:
TechRadar
| 12 Nov 2025
Samsung Galaxy S26 Ultra leak suggests faster wireless charging and larger display
According to a recent leak, the Samsung Galaxy S26 series could feature fast wireless charging support. Some models from the series can …
Source:
India TV News
| 12 Nov 2025